Affective disorders: Neurobio and treatment Flashcards

(34 cards)

1
Q

Neurobiology of major depression

A

Adverse childhood experience
Current Stress (Financial hardship, migration, family, multi genetic factors)
Genetic factors
ALL CONTRIBUTING TO DIRECT decrease in 5HT and NA function and INDIRECTLY same through HPA axis function and cortisol effects leading to depressive syndrome

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Aetiology of depression

A

Multifactorial
Incompletely understood
Interactions of genetic factors, childhood adversities, past hx of mood disorders, psychological predisposition (neuroticism)
Often precipitated by stressful life events

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Monoamine dysfunction in depression

A

All traditional antidepressants affect 5HT/NA systems

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

History of antidepressants

A

Until the 1950s the hypothesis of depression stemmed from intrapsychic conflicts (Freud)
In the 1950s
- Monoamine oxidase inhibitors were introduced. Iproniazid (first MAOi) was used for treatment of TB but found to have antidepressant effects.
- Tricyclics –> (Impapramine)antihistaminic was found to have an antidepressant effect

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

All traditional antidepressants affect:

A

All traditional antidepressants affect 5HT/NA systems

  • -> decreased 5HT concentrations (acute tryptophan depletion) studies (tryptophan is an experimental way to investigate serotonin bc it is the precursor. A way to reduce tryptophan in a noninvasive way is to change diet)
  • -> Reduced 5 HT transporter in post-mortem studies (post mortem studies showed a reduction in 5 HT transporters which further validates the serotonin hypothesis of depression)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

PET studies in depression

A

found a reduction in 5HT transporters

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What part of the brain is the source of Noradrenaline

A

Locus Coeruleus

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What part of the brain is the source of serotonin

A

Raphe Nuclei

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Both serotonin and noradrenaline

A

have ascending tracts to the cerebral cortex and limbic area as well as descending tracts to the spinal cord.
Their cell bodies for these tracts originate in major nuclei of the midbrain.
Each nuclei has ascending tracts which project to brain regions (PFC and limbic system) involved in depressive symptoms as well as ascending and descending tracts involved in pain suppression

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

The monoamine hypothesis of depression

A

suggests a deficiency in synaptic levels of serotonin and noradrenaline in key CNS pathways underlying depressive illness

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Monoamines and depressive symptoms

A
Noradrenaline
- attention
Serotonin
- impulsivity and suicidal ideation
Dopamine 
- psychomotor activation and euphoria
All three
- mood, emotions and cognitive functions
NA and Dopamine
- motivation and enerfgy
Noradrenaline and serotonin
- anxiety and irritability
Serotonin and dopamine
- sleep, appetite, sexual functions and aggressiveness
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

1st generation antidepressants

A

MAOi eg Phenelzine, Tranylcypromine
- Nonselectively inhibit enzymes involved in the breakdown of monoamines including serotonin, dopamine and norepinephrine

TCA eg amytryptiline and clomipramine
- nonselectively inhibit the reuptake of monoamines, including monoamines, including serotonin, dopamine and norepinephrine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

2nd generation antidepressants

A
  • SSRI: eg setraline, citalopram, fluoxetine
  • SN(noradr)RI: eg venlafaxine, duloxetine
  • alpha 2 adrenoreceptor and 5HT2c antagonist (modulate serotonin and NA release) eg Mirtazapine
  • dopamine- noradrenaline reuptake inhibitor eg bupropion
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

SSRIs

A

Efficacy equal to tricyclics in outpatients
Large spectrum of action (OCD, PTSD, Panic, GAD, social anxiety)
Low toxicity and safe in overdose
The initial treatment phase is the most delicate, due to prevalence of side effects over benefits- slow titration
Side effects:
- GI symptoms (nausea, diarrhea)
- Headache, irritability, anxiety
- Reduction of libido and sexual dysfunction

Gradual suspension to avoid withdrawal symptoms (worse with venlafaxine and paroxetine due to short half-life)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Side effects of TCAs

A

Anticholinergic effects eg constipation, dry mouth, drowsiness
cardiac toxicity in overdose
Orthostatic hypotension

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Side effects of MAOi

A

Anticholinergic effects eg dry mouth, GI, drowsiness

Insomnia, food interactions ie tyramine leading to hypertension crises

17
Q

Side effects of venlafaxine

A

nausea, vertigo, headache, insomnia

18
Q

Side effects of mirtazapine

A

drowsiness, sedation, hypotension, increased appetite and weight gain

19
Q

Gene environment interactions evidence for depression

A

People were stratified to two parameters

1) life adversity
2) gene for type of 5HT transporter

20
Q

HPA dysfunction in mood disorders

A

The level of cortisol is higher in people with depressive disorder
If you give the dexamethasone test (night before) then bc of feedback on HPA axis will usually suppress cortisol release the following day

However people with depression do not have the typical suppression after dexamethasone. They continue to have the normal circadian rhythm as if their cortisol was not suppressed. This means there is a reduced sensitivity at GR level and HPA activity

21
Q

Inflammation and depression

A

Raised plasma cytokine levels (IL-6, TNF-α) and inflammatory markers

High comorbidity between chronic inflammation and depression

Administration of cytokines provokes depressive symptoms

Microglial activation in brain of depressed patients (PET studies)

22
Q

Hippocampal size in depression

A

Decreases in size
Also happens when exposed to high levels of cortisol
evidence link?

23
Q

Neural systems involved in depression

A
increased activity (Amy; VST, PFC) to negative emotional stimuli (fearful faces)
decreased activity (VST) to positive emotional stimuli, and during receipt and anticipation of reward 

bias of attention towards negative emotional stimuli, and away from positive emotional and reward- related stimuli

24
Q

Factors that play a role in bipolar disorder

A
Catcholamines
Oxidative stress
Neurotrophins
Inflammation
Stress hormones, glucocorticoids
25
Short term bipolar treatment
to reduce the severity and shorten the duration of the acute episode and achieve remission of symptoms
26
Long term bipolar treatment
prevention of new episodes and to achieve adequate inter-episode control of residual or chronic mood symptoms
27
Overview of drug categories for bipolar disorder treatment
Antipsychotics Lithium Anticonvulsants Antidepressants
28
Antipsychotics
- D2/D3 antagonist 1st generation: Haloperidol - D2/D3 antagonists (also targeting 5-HT) (2nd generation: Olanzapine, Risperidone, Quetiapine, Lurasidone, Asenapine, Amisulpride, Clozapine) - DA partial agonist (Aripiprazole) Rapid anti-manic effect Often used long-term to maintain same treatment effective in acute episode Long-term adverse effects on weight, glucose regulation and lipids [except for Aripiprazole, Amisulpride, and Lurasidone] Full D2 antagonism (Haloperidol) may cause EPSEs
29
Lithium
Element, present in food and drinking water Multiple mechanisms of actions Multiple neurotransmitters (including DA) Cellular signalling Neurotrophic factors Anti-suicidal effects Possible efficacy on impulsive and violent behaviours Strongest evidence for prevention of relapses of any polarity Narrow therapeutic index blood tests every 3 months for the 1st year Adverse long-term effects on Kidney function with excessive levels Risk of Lithium toxicity
30
Anticonvulsants
Anticonvulsants Valproate (valproic acid and sodium valproate) Actions via GABA, intracellular signalling, sodium channel blockade, epigenetic modulation, etc. Anti-manic and effective in prevention of mania Useful in combination, but potential pharmacokinetic interactions not be used for women of child bearing potential because of its unacceptable risk to the foetus of teratogenesis and impaired intellectual development Lamotrigine actions via GABA, Glutamate and sodium channel blockade Mostly effective in prevention of depressive relapses Ineffective as anti-manic agent Carbamazepine less effective in maintenance treatment than lithium but may be used as monotherapy if lithium ineffective especially in patients who do not show the classical pattern of episodic euphoric mania almost exclusively effective against manic relapse pharmacokinetic interactions
31
Treatment of depressive episodes
Antipsychotics (Quetiapine, lurasidone) Fluoxetine/Olanzapine combinations Antidepressants to be co-prescribed with an anti-manic drug Consider Lamotrigine (usually with antimanic drug
32
Treatment of acute manic episodes
Dopamine antagonists (haloperidol, olanzapine, risperidone and quetiapine) Valproate Discontinue any antidepressant treatment
33
Long term treatment of bipolar: prevention of new episodes
Consider long-term treatment following a single severe manic episode Lithium as initial monotherapy (target serum level range: 0.6-0.8 mmol/l) Alternatives (if Lithium ineffective, poorly tolerated or unlikely adherence to treatment): Valproate Dopamine antagonists/partial agonists Carbamazepine
34
Adverse effects of long term pharmacological treatments
``` Weight gain (most medications, particularly Olanzapine and Quetiapine) Metabolic syndrome (Olanzapine, Quetiapine, Risperidone) Hyperprolactinemia (Dopamine antagonists) Tardive dyskinesia (much reduced risk with newer agents) ``` Liver damage (e.g. Valproate) Kidney and Thyroid dysfunction (poorly regulated Lithium)